bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the “notice”) on April 24, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all required periodic financial reports.

bluebird bio Announces Receipt of Expected Notice from Nasdaq

NEW YORK, NY / ACCESSWIRE / April 26, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77240&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on bluebird bio, Inc.(BLUE) Should Contact Levi & Korsinsky About Pending Class Action - BLUE

NEW YORK , April 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

BLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77051&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit – BLUE

NEW YORK , April 25, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against bluebird bio, Inc. ("Blue" or the "Company") (NASDAQ: BLUE) and reminds investors of the May 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Blue To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Blue stock or options between April 24, 2023 and December 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue

Apple

AbbVie

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Blackstone Secured Lending Fund

Colgate-Palmolive

Global stock indices continued an upward trend in March, with both U.S. and non-U.S. stocks rising by 3%.

March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76880&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on bluebird bio, Inc. (BLUE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK , April 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUE

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76184&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc. (BLUE) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76166&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK , April 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the "Class Period"), of the important May 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

LOS ANGELES, CA / ACCESSWIRE / April 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses to Contact the Firm

Novavax

Bluebird Bio's most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.

Better Buy: Bluebird Bio Vs. Novavax

NEW YORK, April 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of bluebird bio Inc. (NASDAQ: BLUE) resulting from allegations that bluebird may have issued materially misleading business information to the investing public. SO WHAT: If you purchased bluebird securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE

OKLAHOMA CITY--(BUSINESS WIRE)-- #BlueBirdBioInc--Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against BlueBird Bio, Inc. (NASDAQ: BLUE).

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against BlueBird Bio, Inc. (NASDAQ: BLUE)

SAN DIEGO--(BUSINESS WIRE)---- $BLUE #BLUE--Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug.

BLUE Shareholders with Significant Losses are Urged to Contact Robbins LLP to Discuss the bluebird bio, Inc. Class Action

NEW YORK , April 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

LOS ANGELES, CA / ACCESSWIRE / April 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=75265&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BLUE

Bluebird Bio has accomplished something few gene-editing specialists have matched. However, the biotech could struggle to keep its operations running for a long time.

Is This Beaten-Down Stock a Good Acquisition Target?

NEW YORK , April 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the "Class Period"), of the important May 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE

LOS ANGELES, CA / ACCESSWIRE / April 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=74992&wire=1 or contact Joseph E. Levi, Esq.

Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning bluebird bio business and prospects, resulting in its stock trading at inflated prices.

BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

News for bluebird bio Stock (BLUE)